UBS

Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.

A Cepheid executive today provided investors with an update on the company's molecular diagnostic pipeline, stating that the firm currently has 14 tests in development for its automated GeneXpert platform and that it expects to offer the broadest test menu of any molecular diagno

Several mass spec vendors presented this week at the UBS Global Life Sciences Conference in New York City, offering information on various aspects of their businesses, including portions of their proteomics portfolios.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The UBS Global Life Sciences Conference concluded on Wednesday with presentations in the afternoon by GenturaDx and Epigenomics.

Speaking at the UBS Global Life Sciences conference in New York on Monday, Bio-Rad Laboratories President and CEO Norman Schwartz told attendees that Bio-Rad planned to launch the platform to test for sexually transmitted diseases.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.